Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study

被引：0
|
作者：
S J Isakoff
D Wang
M Campone
A Calles
E Leip
K Turnbull
N Bardy-Bouxin
L Duvillié
E Calvo
机构：
[1] Massachusetts General Hospital Cancer Center,Division of Hematology and Oncology
[2] and Harvard Medical School,undefined
[3] Phase I Clinical Trials Program,undefined
[4] Henry Ford Hospital,undefined
[5] 2799 West Grand Boulevard,undefined
[6] Institut de Cancerologie de l'Quest—Rene Gauducheau,undefined
[7] Saint Herblain,undefined
[8] START Madrid,undefined
[9] Centro Integral Oncológico Clara Campal,undefined
[10] Hospital Madrid Norte-Sanchinarro,undefined
[11] Oncology Clinical Statistics,undefined
[12] Pfizer Inc,undefined
[13] Oncology Clinical Development,undefined
[14] Pfizer Inc,undefined
[15] 10 Fawcett Street,undefined
[16] Suite 2013,undefined
[17] Oncology Late Phase Strategy Development,undefined
[18] Pfizer Global Research and Development,undefined
[19] Oncology Clinical Development,undefined
[20] Pfizer Global Research and Development,undefined
来源：
British Journal of Cancer | 2014年 / 111卷
关键词：
bosutinib; capecitabine; neoplasms; metastatic cancer; phase 1; safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2058 / 2066
页数：8
相关论文
共 50 条
  • [1] Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study
    Isakoff, S. J.
    Wang, D.
    Campone, M.
    Calles, A.
    Leip, E.
    Turnbull, K.
    Bardy-Bouxin, N.
    Duvillie, L.
    Calvo, E.
    BRITISH JOURNAL OF CANCER, 2014, 111 (11) : 2058 - 2066
  • [2] A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
    Jordan Berlin
    Ramesh K. Ramanathan
    John H. Strickler
    Deepa S. Subramaniam
    John Marshall
    Yoon-Koo Kang
    Robert Hetman
    Matthew W. Dudley
    Jiewei Zeng
    Caroline Nickner
    Hao Xiong
    Philip Komarnitsky
    Stacie Peacock Shepherd
    Herbert Hurwitz
    Heinz-Josef Lenz
    British Journal of Cancer, 2018, 118 : 938 - 946
  • [3] A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
    Berlin, Jordan
    Ramanathan, Ramesh K.
    Strickler, John H.
    Subramaniam, Deepa S.
    Marshall, John
    Kang, Yoon-Koo
    Hetman, Robert
    Dudley, Matthew W.
    Zeng, Jiewei
    Nickner, Caroline
    Xiong, Hao
    Komarnitsky, Philip
    Shepherd, Stacie Peacock
    Hurwitz, Herbert
    Lenz, Heinz-Josef
    BRITISH JOURNAL OF CANCER, 2018, 118 (07) : 938 - 946
  • [4] A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours
    W S Siegel-Lakhai
    A S Zandvliet
    A D R Huitema
    M M Tibben
    G Milano
    V Girre
    V Diéras
    A King
    E Richmond
    J Wanders
    J H Beijnen
    J H M Schellens
    British Journal of Cancer, 2008, 98 : 1320 - 1326
  • [5] A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours
    Siegel-Lakhai, W. S.
    Zandvliet, A. S.
    Huitema, A. D. R.
    Tibben, M. M.
    Milano, G.
    Girre, V.
    Dieras, V.
    King, A.
    Richmond, E.
    Wanders, J.
    Beijnen, J. H.
    Schellens, J. H. M.
    BRITISH JOURNAL OF CANCER, 2008, 98 (08) : 1320 - 1326
  • [6] A phase I dose escalation study of sunitinib plus capecitabine in patients with advanced solid tumors
    Sweeney, C.
    Verschraegen, C.
    Chiorean, G.
    Lee, F.
    Jones, S.
    Tye, L.
    Bello, A.
    Chao, R.
    Burris, H., III
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] A Phase I Dose-Escalation Study of Imatinib Mesylate (Gleevec/STI571) plus Capecitabine (Xeloda) in Advanced Solid Tumors
    Dugan, Elizabeth
    Truax, Roxanne
    Meadows, Kellen L.
    Nixon, Andrew B.
    Petros, William P.
    Favaro, Justin
    Fernando, Nishan H.
    Morse, Michael A.
    Blobe, Gerard C.
    Hurwitz, Herbert I.
    ANTICANCER RESEARCH, 2010, 30 (04) : 1251 - 1256
  • [8] Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
    Freyer, G.
    Isambert, N.
    You, B.
    Zanetta, S.
    Falandry, C.
    Favier, L.
    Trillet-Lenoir, V.
    Assadourian, S.
    Soussan-Lazard, K.
    Ziti-Ljajic, S.
    Fumoleau, P.
    BRITISH JOURNAL OF CANCER, 2012, 107 (04) : 598 - 603
  • [9] Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
    G Freyer
    N Isambert
    B You
    S Zanetta
    C Falandry
    L Favier
    V Trillet-Lenoir
    S Assadourian
    K Soussan-Lazard
    S Ziti-Ljajic
    P Fumoleau
    British Journal of Cancer, 2012, 107 : 598 - 603
  • [10] A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
    Gillessen, Silke
    Gnad-Vogt, Ulrike S.
    Gallerani, Elisa
    Beck, Joachim
    Sessa, Cristiana
    Omlin, Aurelius
    Mattiacci, Maria R.
    Liedert, Bernd
    Kramer, Daniel
    Laurent, Julien
    Speiser, Daniel E.
    Stupp, Roger
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (01) : 35 - 44
12345